Timothy P Cripe MD PhD
Professor, Pediatrics, Ohio State University College of Medicine
Join to View Full Profile
700 Childrens DrColumbus, OH 43205
Phone+1 614-722-3552
Fax+1 614-722-3699
Dr. Cripe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Pediatric Hematology/Oncology, 1993 - 1995
University of Iowa Hospitals and ClinicsResidency, Pediatrics, 1989 - 1992
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1989
Certifications & Licensure
OH State Medical License 1999 - 2027
CO State Medical License 1993 - 2009
WI State Medical License 1995 - 2001
IL State Medical License 1995 - 1999
IA State Medical License 1989 - 1994
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014-2020
Clinical Trials
- HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Start of enrollment: 2010 Mar 01
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Start of enrollment: 2010 Aug 01
- Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors Start of enrollment: 2017 Apr 17
Publications & Presentations
PubMed
- 1 citationsTrabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer.Emily Schwarz, Himanshu Savardekar, Sara Zelinskas, Abigail Mouse, Gabriella Lapurga
Cancer Immunology Research. 2025-04-02 - Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose
Molecular Therapy. Oncology. 2025-03-20 - Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma.Wen Luo, Aliza Gardenswartz, Hai Hoang, Yaya Chu, Meijuan Tian
Molecular Therapy. Oncology. 2024-12-19
Press Mentions
Columbus Cancer Programs Invest in the Future of CareMarch 12th, 2025- TWiPO #93: CureWorks & Caring Cross: Pathways to Advance Cell & Gene Therapy with Dr. Rimas OrentasJanuary 20th, 2022
- Collaboration Between Rheumatologists, Primary Care Reduces Delay in Axial SpA DiagnosisAugust 4th, 2021
- Join now to see all
Grant Support
- A New Paradigm to Prevent and Treat MicrometastasesRESEARCH INST NATIONWIDE CHILDREN'S HOSP2024–2029
- A New Paradigm to Prevent and Treat MicrometastasesRESEARCH INST NATIONWIDE CHILDREN'S HOSP2024–2029
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- Training Program in Basic and Translational Pediatric Oncology ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2022–2027
- IL1RAP CAR NK cells enhance targeting of Ewing Sarcoma (ES) alone and with combinatorial targeted immunotherapyRESEARCH INST NATIONWIDE CHILDREN'S HOSP2021–2025
- IL1RAP CAR NK cells enhance targeting of Ewing Sarcoma (ES) alone and with combinatorial targeted immunotherapyRESEARCH INST NATIONWIDE CHILDREN'S HOSP2021–2025
- Diversity Supplement: Hernandez-Aguirre- Cripe U54RESEARCH INST NATIONWIDE CHILDREN'S HOSP2019–2025
- Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy CenterRESEARCH INST NATIONWIDE CHILDREN'S HOSP2019–2025
- Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy CenterRESEARCH INST NATIONWIDE CHILDREN'S HOSP2019–2025
- Xenograft Core For NF1 Experimental TherapeuticsNational Institute Of Neurological Disorders And Stroke2010–2011
- Phase I Study Of Hsv1716 In Pediatric Non-Cns Solid Tumors,Ind 13196 12/04/2006Food And Drug Administration2010–2011
- Oncolytic HSV Therapy In Immunocompetent Sarcoma ModelsNational Cancer Institute2010
- Xenograft Core For NF1 Experimental TherapeuticsNational Institute Of Neurological Disorders And Stroke2008–2009
- Virotherapy For Neuroblastoma Stem CellsNational Cancer Institute2008–2009
- Oncolytic HSV Therapy In Immunocompetent Sarcoma ModelsNational Cancer Institute2006–2009
- Regulated Toxin Gene Therapy For RhabdomyosarcomaNational Cancer Institute1999–2001
- Regulated Toxin Gene Therapy For RhabdomyosarcomaNational Cancer Institute1997–1999
- HSC 70 And Agnoprotein In Papovavirus AssemblyNational Institute Of Allergy And Infectious Diseases1995–1997
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
